Axol Bioscience has acquired the ophthalmology business of Newcells Biotech in a deal that broadens its range of induced ...

The MarketWatch News Department was not involved in the creation of this content. -- Financing led by US life sciences investor, BroadOak Capital Partners -- Investment to support expansion of US ...

Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive ...

A Cambridge-based biotech specialising in human induced pluripotent stem cell (iPSC) technologies has taken on the ophthalmology business of a drug discovery partner in Newcastle.

CAMBRIDGE, England--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that ...

Axol Bioscience and Censo Biotechnologies have merged to set up a one-stop-shop for induced pluripotent stem cells (iPSCs). IPSCs are derived from skin or blood cells that have been reprogrammed back ...

Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, has announced that ...

The relationship brings together Horizon’s precision genome editing capability and Axol’s expertise in iPSC reprogramming and differentiation to provide isogenic cell lines for neuronal and ...

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and ...

Financing led by US life sciences investor, BroadOak Capital Partners Investment to support expansion of US operations, product development, and cell manufacturing scale-up Axol Bioscience Ltd. (Axol) ...